Plutux
$6.89
+6.33%
2026-09-04 12:20:32 EDT+$0.41
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Negociación activa

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, ...

Evolución del precio

$6.89
+6.33%+$0.41
Máximo
Mínimo
Máx. 52s-90.0%
Vol. rel.
Intervalo
Rango5.6h
VolumenSMA5SMA10
Regencell Bioscience Holdings Limited (NASDAQ: RGC) is an early-stage, TCM-focused healthcare company that applies bioscience R&D to develop therapeutic approaches aimed at neurocognitive disorders and degenerative conditions. The company’s core business model centers on advancing Traditional Chinese Medicine (TCM) programs through research, development, and market introduction, with a particular emphasis ...Regencell Bioscience Holdings Limited (NASDAQ: RGC) is an early-stage, TCM-focused healthcare company that applies bioscience R&D to develop therapeutic approaches aimed at neurocognitive disorders and degenerative conditions. The company’s core business model centers on advancing Traditional Chinese Medicine (TCM) programs through research, development, and market introduction, with a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Headquartered in Causeway Bay, Hong Kong, Regencell operates within the drug manufacturing/specialty & generic drug industry classification, but its differentiator is its TCM-oriented development pathway targeted at neurocognitive outcomes. From a products/services perspective, the company’s activities are best understood as an R&D pipeline and commercialization program for TCM therapeutics (and related formulations/solutions) intended to address neurocognitive disorders and degeneration. The company also communicates an “investor relations” narrative around advancing TCM treatments—indicating a process that likely includes clinical evaluation, regulatory engagement, and commercialization planning typical for therapeutics companies. Its relatively small employee base (about 10 employees as of June 30, 2025) suggests a lean operating structure common to companies in clinical development or pre-commercial stages, where external partnerships, contract research, and specialized vendors may play a larger role than in fully scaled manufacturing operations. On financial and cost structure considerations, the available market data shows that Regencell is valued at a little over $2.6B market capitalization (as provided) and is categorized by specialty drug/biotech market dynamics. While specific cost-of-goods breakdowns and bill-of-materials (BOM) details are not provided in the supplied material, TCM therapeutics typically involve sourcing botanical/raw materials, formulation development, quality control, stability testing, and (depending on the product format) manufacturing and packaging—areas where costs are commonly driven by raw-material standardization, process validation, and compliance. In early-stage development, overhead and R&D spending tend to dominate, and financial metrics may reflect investment phases rather than mature revenue generation. Key people at Regencell include Yat-Gai Au, who serves as Chairman & Chief Executive Officer and is described as the founder of the company. Corporate communications and leadership presence are therefore closely tied to the founder/CEO role. As for “wishes” or strategic direction implied by the company’s framing, Regencell’s stated mission emphasizes saving and improving lives by developing TCM-based therapies for ADHD and ASD—reflecting an ambition to translate TCM heritage into clinically relevant therapeutic options for neurocognitive disorders. The company’s ongoing development and commercialization efforts align with a healthcare-focused growth plan aimed at bringing new therapeutic solutions to patients and stakeholders.
Fundación
2014
Empleados
10
CEO
Yat-Gai Au
Nombre completo
Regencell Bioscience Holdings Limited
Sector
Healthcare
Industria
Drug Manufacturers - Specialty & Generic
ROE
-231.87%
Capitalización
$3.41B
Ratio corriente
1.42
WACC
11.57%
ROIC
-563.83%

Información de contacto

852 2155 0823
Chinachem Leighton Plaza, Hong Kong KY1-1107

Acciones relacionadasDrug Manufacturers - Specialty & Generic

Ver todas las acciones de EE. UU.

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

© Plutux Technology Limited 2026